Skin and Soft-Tissue Infections: A Critical Review and the Role of Telavancin in Their Treatment

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S69-S78

  Cardona, Amilcar F ^a   Wilson, Samuel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cellulitis; necrotizing infections; skin infections; soft tissue infections; telavancin

Indexed keywords

CEFTAROLINE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; ORITAVANCIN; TEDIZOLID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ABSCESS; ABSCESS DRAINAGE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CELLULITIS; CLINICAL TRIAL (TOPIC); COAGULASE NEGATIVE STAPHYLOCOCCUS; DEBRIDEMENT; DIABETES MELLITUS; DISEASE PREDISPOSITION; DISEASE SEVERITY ASSESSMENT; ENDOCARDITIS; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; INCIDENCE; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NECROTIZING FASCIITIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT INDICATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NORTH AMERICA; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DAPTOMYCIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 84941568779     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ528     Document Type: Article

References (86)

1. Barie PS,Wilson SE. Impact of evolving epidemiology on treatments for complicated skin and skin structure infections: the surgical perspective. J Am Coll Surg 2015; 220:105-16.e6.
2. Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med 2012; 79:57-66.
3. May AK. Skin and soft tissue infections: the new surgical infection society guidelines. Surg Infect (Larchmt) 2011; 12:179-84.
4. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52(suppl 1):i3-17.
5. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147-59.
6. US. Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM071185.pdf. Accessed 8 February 2015.
7. Centers for Disease Control and Prevention. CDC/NHSN surveillance definitions for specific types of infections. Available at: http://www.cdc. gov/nhsn/PDFs/pscManual/17pscNosInfDef-current.pdf. Accessed 8 February 2015.
8. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008; 19:173-84.
9. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis 2013; 13:252.
10. Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005; 5:501-13.
11. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; 15:1516-8.
12. Suaya JA, Mera RM, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis 2014; 14:296.
13. Magill SS, Hellinger W, Cohen J, et al. Prevalence of healthcare-associated infections in acute care hospitals in Jacksonville, Florida. Infect Control Hosp Epidemiol 2012; 33:283-91.
14. Najjar-Pellet J, Smink DS. Prophylactic antibiotics and prevention of surgical site infections. Surg Clin North Am 2015; 95:269-83.
15. MeeksDW, Lally KP, Carrick MM, et al. Compliancewith guidelines to prevent surgical site infections: as simple as 1-2-3?AmJ Surg 2011; 201:76-83.
16. Centers for Disease Control and Prevention. National hospital discharge survey, 2010. Available at: http://ftp.cdc.gov/pub/Health-Statistics/NCHS/Dataset-Documentation/NHDS/NHDS-2010-Documentation.pdf. Accessed 10 February 2015.
17. Mu Y, Edwards JR, Horan TC, Berrios-Torres SI, Fridkin SK. Improving risk-adjusted measures of surgical site infection for the national healthcare safety network. Infect Control Hosp Epidemiol 2011; 32: 970-86.
18. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health careassociated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007; 122:160-6.
19. Centers for Disease Control and Prevention. CDC surgical site infection (SSI) event. 2015. Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf. Accessed 5 July 2015.
20. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198-208.
21. Hawn MT, Vick CC, Richman J, et al. Surgical site infection prevention: time to move beyond the surgical care improvement program. Ann Surg 2011; 254:494-9; discussion 499-501.
22. Anthony T, Murray BW, Sum-Ping JT, et al. Evaluating an evidencebased bundle for preventing surgical site infection: a randomized trial. Arch Surg 2011; 146:263-9.
23. Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29(suppl 1):S51-61.
24. Anthony T, Long J, Hynan LS, et al. Surgical complications exert a lasting effect on disease-specific health-related quality of life for patients with colorectal cancer. Surgery 2003; 134:119-25.
25. Baddour LM. Cellulitis and erysipelas. Available at: http://www. uptodate.com/contents/cellulitis-and-erysipelas?source=preview& search=cellulitis&language=en-US&anchor=H1&selectedTitle=1~150#H1. Accessed 1 June 2015.
26. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591-4.
27. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996; 23:1162-4.
28. Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am 2002; 16:697-712.
29. Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis 2001; 33:35-40.
30. Centers for Disease Control and Prevention. Soft tissue infections among injection drug users-San Francisco, California, 1996-2000. MMWR Morb Mortal Wkly Rep 2001; 50:381-4.
31. Lavender TW, McCarron B. Acute infections in intravenous drug users. Clin Med 2013; 13:511-3.
32. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26:510-3.
33. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41:281-8.
34. Suaya JA, Eisenberg DF, Fang C, Miller LG. Skin and soft tissue infections and associated complications among commercially insured patients aged 0-64 years with and without diabetes in the U.S. PLoS One 2013; 8:e60057.
35. Dryden M. Complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus: epidemiology, risk factors, and presentation. Surg Infect (Larchmt) 2008; 9(suppl 1):S3-10.
36. Jeng A, Beheshti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 2010; 89:217-26.
37. Ray GT, Suaya JA, Baxter R. Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 76:24-30.
38. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010; 51:895-903.
39. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol 2007; 28:1290-8.
40. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57:7-13.
41. Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45:287-93.
42. Zilberberg MD, Shorr AF, Micek ST, et al. Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare-associated infection risk factors. Infect Control Hosp Epidemiol 2009; 30:1203-10.
43. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010; 65(suppl 4):iv17-31.
44. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against 10,956 organisms causing acute bacterial skin and skin structure infections in the United States medical centers [poster C2-1628]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO: 10-13 September 2013.
45. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:1047-53.
46. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63:1459-80.
47. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillinresistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144:309-17.
48. Awad SS, Elhabash SI, Lee L, Farrow B, Berger DH. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg 2007; 194:606-10.
49. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
50. Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012; 50:238-45.
51. Mazuski JE. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt) 2008; 9:567-71.
52. Stevens DL, Baddour LM. Necrotizing soft tissue infections. Available at: http://www.uptodate.com/contents/necrotizing-soft-tissue-infections? source=preview&search=necrotizing+fasciitis&language=e. http://www. uptodate.com/contents/necrotizing-soft-tissue-infections?source= preview&search=necrotizing+fasciitis&language=en-US&anchor= H1&selectedTitle=1~91#H8. Accessed 11 February 2015.
53. El-Khani U, Nehme J, Darwish A, et al. Multifocal necrotising fasciitis: an overlooked entity? J Plast Reconstr Aesthet Surg 2012; 65:501-12.
54. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240-5.
55. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-7.
56. Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 2007; 45:450-8.
57. Kaul R, McGeer A, Low DE, Green K, Schwartz B. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103: 18-24.
58. Anaya DA, McMahon K, Nathens AB, Sullivan SR, Foy H, Bulger E. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 2005; 140:151-7; discussion 158.
59. Huang KF, Hung MH, Lin YS, et al. Independent predictors of mortality for necrotizing fasciitis: a retrospective analysis in a single institution. J Trauma 2011; 71:467-73; discussion 473.
60. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003; 85-A:1454-60.
61. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1:69-78.
62. Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003; 185:369-75.
63. May AK, Stafford RE, Bulger EM, et al. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2009; 10:467-99.
64. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
65. Edelsberg J, Berger A,Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29:160-9.
66. Jafari Saraf L,Wilson SE. Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections. Infect Drug Resist 2011; 4:87-95.
67. Bartlett JG. Methicillin-resistant Staphylococcus aureus infections. Top HIV Med 2008; 16:151-5.
68. Dancer SJ. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008; 61:246-53.
69. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-6.
70. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15.
71. Kowalski TJ, Berbari EF, Osmon DR. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 2005; 80:1201-7; quiz 1208.
72. Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15-9.
73. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009; 41:4-9.
74. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005; 40:280-5.
75. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010; 30:80-94.
76. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41.
77. Parish D, Scheinfeld N. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs 2008; 9:201-9.
78. Anderson SD, Gums JG. Ceftobiprole: an extended-spectrum antimethicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother 2008; 42:806-16.
79. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52:4442-7.
80. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221-9.
81. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008; 62(suppl 1):i11-6.
82. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683-93.
83. Health Canada. PrVibativ® 2010. Available at: http://www.hc-sc.gc.ca/dhpmps/alt-formats/pdf/prodpharma/sbd-smd/phase1-decision/drugmed/sbd-smd-2010-vibativ-107792-eng.pdf. Accessed 19 March 2015.
84. VIBATIV (telavancin) Prescribing Information. Theravance Biopharma Antibiotics, Inc. December 2014. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2014/022110s011lbl.pdf. Accessed 9 March 2015.
85. Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 2009; 197:791-6.
86. Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN. Update of the telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis 2015; 81: 275-9.